SNY

Sanofi SA

Add to Watchlist

Advanced Chart

47.210

+0.08(0.170%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

47.560

Open

47.270

VWAP

47.29

Vol

2.77M

Mkt Cap

57.95B

Low

47.070

Amount

131.04M

EV/EBITDA(TTM)

7.98

Total Shares

2.50B

106.54B

EV/OCF(TTM)

7.52

P/S(TTM)

2.21

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2029Q1

FY2029Q2

FY2029Q3

12.63B

-6.04%

1.591

+3.01%

11.30B

+6.92%

1.006

+47.5%

10.88B

+9.99%

0.961

-5.96%

Estimates Revision

The market is revising Downward the revenue expectations for Sanofi (SNY) for FY2025, with the revenue forecasts being adjusted by -0.09% over the past three months. During the same period, the stock price has changed by -7.54%.

Revenue Estimates for FY2025

Revise Downward

-0.09%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.98%

In Past 3 Month

Stock Price

Go Down

-7.54%

In Past 3 Month

5 Analyst Rating

29.63% Upside

Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 61.20 USD with a low forecast of 56.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

0 Sell

Moderate Buy

29.63% Upside

Current: 47.210

Low

56.00

Averages

61.20

High

67.00

29.63% Upside

Current: 47.210

Low

56.00

Averages

61.20

High

67.00

JPMorgan

Richard Vosser

Neutral -> Overweight

upgrade

2025-08-08

New

Reason

JPMorgan

Richard Vosser

Price Target

2025-08-08

New

upgrade

Neutral -> Overweight

Reason

JPMorgan analyst Richard Vosser upgraded Sanofi to Overweight from Neutral with a price target of EUR 105, down from EUR 110. The firm sees positive risk/reward into the company's data readouts as it believes little pipeline value is being priced into the shares. Sanofi is undervalued even in the unlikely event of these assets being worth zero, the analyst tells investors in a research note. JPMorgan says Sanofi is trading at a 20% discount to the sector.

Deutsche Bank

Emmanuel Papadakis

Hold

downgrade

2025-08-05

Reason

Deutsche Bank

Emmanuel Papadakis

Price Target

2025-08-05

downgrade

Hold

Reason

Deutsche Bank analyst Emmanuel Papadakis lowered the firm's price target on Sanofi to EUR 90 from EUR 100 and keeps a Hold rating on the shares.

Barclays

Emily Field

Overweight

downgrade

2025-07-02

Reason

Barclays

Emily Field

Price Target

2025-07-02

downgrade

Overweight

Reason

Barclays analyst Emily Field lowered the firm's price target on Sanofi to EUR 115 from EUR 125 and keeps an Overweight rating on the shares.

BTIG

Jeet Mukherjee

Buy

maintain

$55 -> $59

2025-06-26

Reason

BTIG

Jeet Mukherjee

Price Target

$55 -> $59

2025-06-26

maintain

Buy

Reason

BTIG analyst Jeet Mukherjee raised the firm's price target on Kymera Therapeutics (KYMR) to $59 from $55 and keeps a Buy rating on the shares. The company has announced the decision to advance next-gen IRAK4 degrader, KT-485, over KT-474 currently in Phase 2 studies, and while the decision delays the time to key Phase 2 data, the firm sees it as a long-term positive, allowing Kymera and Sanofi (SNY) to advance a molecule with greater selectivity and potency, the analyst tells investors in a research note.

Stifel

Alex Thompson

Buy

maintain

$45.96

2025-06-25

Reason

Stifel

Alex Thompson

Price Target

$45.96

2025-06-25

maintain

Buy

Reason

Stifel analyst Alex Thompson is reiterating a Buy rating on Kymera Therapeutics (KYMR) following "a slate of updates," including the decision by partner Sanofi (SNY) to discontinue development of lead IRAK4 degrader KT-474 in favor of next-gen KT-485 and a new partnership deal with Gilead (GILD) for a CDK2 molecular glue degrader. While the update related to IRAK4 is "disappointing and removes potential catalysts" next year, Sanofi expects to move KT-485 into Phase 1 next year and the broader partnership remains in place, notes the analyst. On the Gilead deal, Kymera will receive up to $85M in upfront and options, adds the analyst, who would view any weakness from today's news as a buying opportunity as the firm contends there remains limited credit in the stock for the broader pipeline and additional milestone payments. Stifel has a Buy rating on Kymera shares, which are down $1.18, or 2.5%, to $45.96 in morning trading.

Guggenheim

Buy

maintain

2025-06-03

Reason

Guggenheim

Price Target

2025-06-03

maintain

Buy

Reason

Guggenheim raised the firm's price target on Sanofi (SNY) to EUR 110 from EUR 108 and keeps a Buy rating on the shares after the company announced its planned acquisition of Blueprint Medicines (BPMC). Following last week's mixed results for itepekimab, which put additional pressure on the company to build out its mid to late stage pipeline, the firm likes this deal given its synergy with Sanofi's portfolio and opportunities for broad expansion, the analyst tells investors.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Sanofi SA (SNY.O) is 9.89, compared to its 5-year average forward P/E of 10.93. For a more detailed relative valuation and DCF analysis to assess Sanofi SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

10.93

Current PE

9.89

Overvalued PE

13.56

Undervalued PE

8.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Strongly Undervalued

5Y Average EV/EBITDA

9.21

Current EV/EBITDA

7.57

Overvalued EV/EBITDA

9.85

Undervalued EV/EBITDA

8.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

2.62

Current PS

2.15

Overvalued PS

2.84

Undervalued PS

2.40